Debra Heffernan
- Democratic
- Representative
- District 6
Primary
Currently the US FDA is reviewing a New Drug Application (NDA) of a pharmaceutical product containing cannabidiol (CBD) to treat patients with rare pediatric seizure disorders. If approved, this drug will be required to be prescribed and dispensed like other FDA approved products. However, to make sure that this product and future FDA approved marijuana containing products are available to patients as soon as possible, a change in Delaware law is required. This bill would exempt federally lawful FDA approved marijuana containing products from Schedule I of the state’s Controlled Substances Act until they are rescheduled under Delaware law. This would allow patient access to new therapies without an administrative delay, and allow FDA approved marijuana containing medicines to be prescribed, dispensed and regulated like other FDA approved pharmaceutical products. Illegal possession or sale of these drugs would be prosecuted as any other violation of the Controlled Substance Act.
Signed by Governor
Passed By Senate. Votes: 21 YES
Reported Out of Committee (Health, Children & Social Services) in Senate with 3 On Its Merits
Assigned to Health, Children & Social Services Committee in Senate
Passed By House. Votes: 41 YES
Reported Out of Committee (Health & Human Development) in House with 8 On Its Merits
Introduced and Assigned to Health & Human Development Committee in House
| Bill Text Versions | Format |
|---|---|
| Bill Text | HTML PDF |
| Document | Format |
|---|---|
| No related documents. |
Data on Open States is updated periodically throughout the day from the official website of the Delaware General Assembly.
If you notice any inconsistencies with these official sources, feel free to file an issue.